Drugs / JLP-2008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06165965 | May → Jun 2022 | — | Jeil Pharmaceutical Co., Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JLP-2008 | “JLP-2008 Fixed-Dose Combination Tablet Demonstrates Bioequivalence and Comparable Safety to Separate Dapagliflozin + Pioglitazone in Healthy Participants.” PMID 42270920 ↗ Jun 2026 |
| Action | Inhibit | “SGLT2 dual inhibitor” NCT06165965 ↗ |
| Route | Oral | “single oral dosing” NCT06165965 ↗ |